Alliance Development

BIO’s Mission is to be the champion for biotechnology. We advocate for policies that will enable the realization of biotechnology’s promise for providing breakthrough products to cure disease, protecting against bio-terrorism, feeding the hungry, and cleaning our environment.

Kimball Thomson, President & CEO of BioUtah discusses his organization and what makes Utah a good place for innovative industry growth.

Bioscience economic development in a nation as large and diverse as the United States is as varied as the country itself.  A complex array of factors influence the allocation of resources and the nature of bioscience industry development.

Tracey Mumford from The Michael J. Fox Foundation discusses Parkinson's disease, the Foundation’s work toward a cure, and partnerships they're currently seeking. The Foundation will be one of the patient advocacy groups attending the 2012 BIO International Convention on June 18-21 in Boston, Mass.  

Lisa Tate, CEO of WomenHeart, the National Coalition for Women with Heart Disease, discusses what we can each do to prevent heart disease.

State governments in 2011 continued to see regional economic growth in the life sciences industry and in 2012 will increasingly focus attention on technology transfer and venture funding as mechanisms to increase private sector innovation related activities within their jurisdictions. Realizing that entrepreneurship is a key ingredient in economic development, states and localities are undertaking the support of programs that assist high technology businesses, and that capitalize on state regional presence of universities and federal laboratories.

Aaron Miscenich, president of the New Orleans BioInnovation Center and chairman of LouisianaBio, discusses the bioscience economic development initiatives.

New Orleans shows the signs of a city reborn from the destruction brought on by Hurricane Katrina.  The changes in the city’s infrastructure and building projects have certainly been among them.  The city reached a  milestone its renaissance when the New Orleans BioInnovation Center (NOBIC) opened for business.

With more than one-fifth of the world’s population, China is an important market for biotech products and is increasingly a key global player in biotech research, development and manufacturing.

A strong Network will bolster public awareness of the industry and encourage more investment dollars.

Dr. Augustus White is a pioneer in equitable care. He will be delivering the keynote address at this year’s Diversity Summit at the 2011 BIO International Convention.

Scientific American will release the third annual Worldview: A Global Biotechnology Perspective at this year's BIO International Convention.

The keys to successful industrial biotech business relationships mirror those for successful personal relationships, industry leaders explained today.  During the final Lunch Plenary Session of BIO’s 2011 World Congress in Toronto, moderator James Stoppert, CEO of BioAdvisors, along with panelists Patrick Gruber, CEO of Gevo, Ron Commander, Head of Butyl Rubber Business Unit at Lanxess, Christophe Schilling, CEO of Genomatica, and Hisao Urata, General Manager of Corporate Planning at Mitsubishi Chemical discussed “Strategic Partnerships for More Robust Value Chains” and identified some key components to that end.

Partnering decisions can make or break a company’s value. Pursuing the right partnership deal can ultimately increase a company’s value but conversely, the wrong decision can ultimately kill a company’ value.

This month, BIO is leading a delegation of biopharma CEOs to China for meetings with members of the Chinese biotech community and government leaders. The mission illustrates a strong commitment on behalf of the western biotechnology industry to encourage China to strengthen its support for biotech innovation and take steps to enhance greater investment and collaboration with companies in China. The series of meetings between China’s local industry and government leaders and biotech CEOs will lay the foundation for increased cooperation to help biotech flourish in China.

Letters, Testimony & Comments

May 8 2013
BIO  urges Florida Governor Scott to sign House Bill 365 – a bill related to the substitution of biologic and biosimilar medicines – which recently passed out of the Legislature.
February 1 2013
BIO supports passage of Florida House Bill 365, which provides requirements for pharmacist to dispense substitute biological products that are determined to be interchangeable for prescribed biological product.
January 24 2013
To ensure transparency and communication between patients and their treatment teams, BIO believes that certain safeguards should guide substitution policies for interchangeable biologics under state law as well.
January 24 2013
The policies outlined in Senate Bill 2190 align with all five of BIO’s Principles on Biologic Product Substitution and we therefore support its passage.
January 24 2013
BIO opposes the proposal to subject certain cancer therapies to prior authorization measures under Senate Bill 2066.

Press Releases

June 23 2015
Governor Greg Abbott for signed critical legislation to create a pathway for the substitution of interchangeable biologic medicines.
June 11 2015
BIO continues its continued opposition to The Innovation Act (H.R.9) as amended and reported by the House Judiciary Committee today.
June 5 2015
BIO issued the following statement regarding the mark-up of The Protecting American Talent and Entrepreneurship (PATENT) Act
May 22 2015
BIO & NCBIO commend Governor Pat McCrory for signing critical legislation to create a pathway for the substitution of interchangeable biologic medicines.